Document is current
Any future updates will be listed below
-
Authors
Imamura, Sayumi https://orcid.org/0009-0007-8486-6475
Mori, Kiyoshi https://orcid.org/0000-0002-5129-9597
Yasojima, Hiroyuki https://orcid.org/0009-0005-3729-1520
Mizutani, Makiko
Okada, Kumiko
Hayashi, Chie https://orcid.org/0000-0002-6609-042X
Mano, Masayuki
Masuda, Norikazu https://orcid.org/0000-0002-7302-0278
- License Information
-
More Information
Article History
Received: 12 June 2025
Accepted: 30 September 2025
First Online: 4 November 2025
Declarations
:
: This retrospective observational study was conducted under the umbrella of “A multicenter cohort study to build better breast cancer care and consensus based on the real-world evidence (KBCSG-TR 1316), which was approved by the Central Ethics Committee of NHO Osaka National Hospital (Osaka, Japan) and registered at the UMIN-CTR (UMIN000049957, on January 3rd, 2023). The study was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived given the retrospective noninvasive nature of the study.
: Informed consent to publish the study data was obtained from all patients.
: Masuda N reports receiving honoraria (e.g. lecture fees) from AstraZeneca, Chugai, Daiichi Sankyo, Eli-Lilly, and Pfizer; research funding to institution from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli-Lilly, Gilead Sciences, Kyowa-Kirin, MSD, Novartis, Ono-Pharma, and Pfizer; being a member of board of directors for Japanese Breast Cancer Society (JBCS), Japan Society of Clinical Oncology (JSCO), and Japan Breast Cancer Research Group Association (JBCRG). All other authors have no competing interests.
